Private company
Evelo Biosciences, Inc.
American pharmaceutical preparations company, incorporated in Delaware.
Last updated Oct 18, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Research and development | $9.1M3 | $20.0M4 | $39.9M4 | $63.1M5 | $69.6M6 | $83.6M7 | $78.6M7 | |
| Operating income | -$13.0M3 | -$27.5M4 | -$58.1M4 | -$86.4M5 | -$91.9M6 | -$115.4M7 | -$108.5M7 | |
| Income tax | $04 | $04 | $190.0K5 | $409.0K6 | $428.0K7 | $930.0K7 | ||
| Net income | -$13.3M3 | -$28.0M4 | -$56.9M4 | -$85.5M5 | -$93.7M6 | -$122.2M7 | -$114.5M7 | |
| Earnings per share | -$2.376 | -$2.317 | -$1.317 | |||||
| Earnings per share (diluted) | -$2.376 | -$2.317 | -$1.317 |
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Cash | $15.8M4 | $38.2M3 | $93.1M4 | $77.8M5 | $68.9M6 | $68.4M7 | $47.9M7 | |
| Current assets | $38.8M3 | $151.6M4 | $81.0M5 | $71.0M6 | $71.0M7 | $51.6M7 | ||
| Total assets | $43.8M3 | $159.9M4 | $90.9M5 | $90.6M6 | $87.9M7 | $64.4M7 | ||
| Current liabilities | $3.8M3 | $9.2M4 | $9.7M5 | $19.8M6 | $17.4M7 | $12.4M7 | ||
| Long-term debt | $10.0M3 | $12.3M4 | $19.6M5 | $30.0M6 | $46.6M7 | $43.6M7 | ||
| Total liabilities | $14.8M3 | $22.9M4 | $30.7M5 | $60.2M6 | $79.2M7 | $69.4M7 | ||
| Shareholders’ equity | -$28.3M4 | -$54.7M4 | $136.9M5 | $60.2M6 | $30.5M7 | $8.7M7 | -$5.0M7 | |
| Shares outstanding | 3.9M shares3 | 31.8M shares4 | 32.2M shares5 | 47.5M shares6 | 53.6M shares7 | 53.6M shares6 | 110.9M shares7 |
Leadership
Who has led Evelo Biosciences, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
20202025
- Chief executive officerSimba Gill May 8, 2018 to Nov 8, 202310
- PresidentMark Bodmer Jan 16, 2019 to Nov 8, 202311
- PresidentSimba Gill May 8, 2018 to Nov 8, 202310
- Chief financial officerMarella Thorell Jul 18, 2022 to Nov 8, 202312
- Chief financial officerLuca Scavo Jun 3, 2021 to Jan 21, 202213
Board members and other officers (22)
- Chief Development OfficerJonathan B. Zung Jan 4, 2021 to Oct 14, 202214
- Chief Commercial OfficerMark D. Plinio Jun 16, 2021 to Feb 2, 202315
- Principal Accounting OfficerStephen J. Carriere Sep 29, 2021 to Jan 23, 202316
- Chief Development OfficerNeil Graham Apr 10, 2020 to Apr 10, 202017
- Chief Medical OfficerDuncan McHale May 8, 2018 to Nov 8, 202318
- OfficerMark Bodmer May 8, 2018 to May 10, 201819
- Board memberRobert L. Rosiello Apr 18, 2023 to Jun 12, 202320
- Board memberAlexander C. Reynolds Jul 12, 2023 to Jul 12, 202321
- Board memberJeffrey R. Moore Jul 12, 2023 to Jul 12, 202322
- Board memberTonya Williams Apr 5, 2022 to Jun 12, 202323
- Board memberJohn Hohneker Jan 29, 2021 to Jun 12, 202324
- Board memberJulie McHugh Apr 13, 2021 to Jun 12, 202325
- Board memberIain B. McInnes Sep 7, 2021 to Jun 12, 202326
- Board memberJose-Carlos Gutierrez-Ramos Jun 14, 2019 to Jun 12, 202327
- Board memberJuan Andres Dec 6, 2019 to Jun 12, 202328
- Board memberDavid R. Epstein May 8, 2018 to Jun 30, 202229
- Board memberKyriazi Theo Melas May 8, 2018 to Jun 12, 202330
- Board memberLord Ara Darzi May 8, 2018 to Jun 13, 202231
- Board memberNancy A. Simonian May 8, 2018 to Jun 18, 202032
- Board memberNoubar Afeyan May 8, 2018 to Jun 13, 201933
- Board memberSimba Gill May 8, 2018 to Nov 8, 202310
- General counselDaniel Char Nov 1, 2018 to Oct 14, 202234
Timeline
- May 8, 2018New chief executive Simba Gill becomes CEO10
Filings
177 filings to the SEC since October 2021: 2 annual reports, 8 quarterly reports, 42 major events, 88 insider forms, 17 large holders, 20 other. The latest 20:
- Mar 8, 2024EFFECT EDGAR
- Jan 26, 202415-12G EDGAR
- Jan 26, 2024S-8 POS EDGAR
- Jan 26, 2024S-8 POS EDGAR
- Jan 26, 2024POS AM EDGAR
- Jan 26, 20248-K EDGAR
- Dec 12, 2023DEFA14A EDGAR
- Dec 12, 2023DEF 14A EDGAR
- Dec 11, 2023SC 13G/A EDGAR
- Dec 4, 20238-K EDGAR
- Dec 1, 2023PRE 14A EDGAR
- Nov 21, 20238-K EDGAR
- Nov 13, 2023SC 13G/A EDGAR
- Nov 9, 202310-Q EDGAR
- Nov 8, 20234 EDGAR
- Nov 8, 20234 EDGAR
- Nov 8, 20234 EDGAR
- Nov 8, 20234 EDGAR
- Nov 3, 20234 EDGAR
- Nov 3, 20234 EDGAR
The 177 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 17 such filings since October 2021, the latest 10:
- Dec 11, 2023SC 13G/A
- Nov 13, 2023SC 13G/A
- Aug 10, 2023SC 13G
- Jul 21, 2023SC 13G
- Jul 13, 2023SC 13D/A
- Jul 10, 2023SC 13G/A
- Jun 12, 2023SC 13G/A
- Feb 21, 2023SC 13D/A
- Feb 14, 2023SC 13G/A
- Feb 9, 2023SC 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10SEC EDGARSimba Gill, Chief executive officer
- 11SEC EDGARMark Bodmer, President
- 12
- 13SEC EDGARLuca Scavo, Chief financial officer
- 14
- 15
- 16
- 17
- 18SEC EDGARDuncan McHale, Chief Medical Officer
- 19SEC EDGARMark Bodmer, Officer
- 20SEC EDGARRobert L. Rosiello, Board member
- 21SEC EDGARAlexander C. Reynolds, Board member
- 22SEC EDGARJeffrey R. Moore, Board member
- 23SEC EDGARTonya Williams, Board member
- 24SEC EDGARJohn Hohneker, Board member
- 25SEC EDGARJulie McHugh, Board member
- 26SEC EDGARIain B. McInnes, Board member
- 27
- 28SEC EDGARJuan Andres, Board member
- 29SEC EDGARDavid R. Epstein, Board member
- 30SEC EDGARKyriazi Theo Melas, Board member
- 31SEC EDGARLord Ara Darzi, Board member
- 32SEC EDGARNancy A. Simonian, Board member
- 33SEC EDGARNoubar Afeyan, Board member
- 34SEC EDGARDaniel Char, General counsel